All News

Found 265 articles

• KemPharm, Inc. Appoints Todd Johnson, Ph.D. as Chief Commercial Officer

  6/23/2010

• KemPharm, Inc. Announces Entering Into an Exclusive Supply Agreement With Johnson Matthey Inc. for KP201

  5/18/2010

• KemPharm, Inc. Announces Positive Results from Phase 1 Trial of KP106 for ADHD

  1/11/2010

• KemPharm, Inc. Announces Initiation of Phase 1 Trial of KP106 for ADHD

  10/22/2009

• KemPharm, Inc. Expands Prodrug Pipeline with Candidate for Treatment of Pain and Closes Series B Financing

  9/16/2009